Taking the red out of rosacea: Topical alpha-1-adrenergic receptor agonist shows promise
Publish date: August 1, 2008
Cheryl Guttman
Cheryl Guttman
Topical treatment with a 0.05 percent solution of oxymetazoline in a small series of patients with erythematotelangiectatic rosacea has been associated with encouraging efficacy for reducing erythema and preventing erythematous flares. Aspect Pharmaceuticals is planning a clinical trial of a formula optimized for dermatologic use.